Myriad Genetics Reduced 2019 Guidance, but Is It Really So Bad?
The genetic testing pioneer lost $500 million in value after reporting fiscal Q3 operating results.
Myriad Genetics
MYGN
MYGN
$24.57
$0.43
0.0%
BATS BZX Real Time Price as of May 24, 2019, 3:38 p.m.
View Interactive MYGN Charts
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
News & Analysis: Myriad Genetics
The Fool has written over 100 articles on Myriad Genetics.
All
Market Moves
Earnings
Why Marathon Petroleum, Livent, and Myriad Genetics Slumped Today
These stocks struggled on a mixed day on Wall Street.
Myriad Genetics Inc (MYGN) Q3 2019 Earnings Call Transcript
MYGN earnings call for the period ending March 31, 2019.
Top Gene-Sequencing Stocks for 2019
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
Here's Why Genetic Testing Stocks Rose as Much as 42.9% in February
Quarterly earnings from around the industry suggested the epic growth opportunity isn't slowing down anytime soon.
Myriad Genetics Inc (MYGN) Q2 2019 Earnings Conference Call Transcript
MYGN earnings call for the period ending December 31, 2018
Here's Why Myriad Genetics Lost 28.4% in November
The genetic testing pioneer announced fiscal first-quarter 2019 results, but had to reduce full-year revenue guidance.
This High-Growth Biotech Industry Is as Competitive as Ever Heading Into 2019
Three short years ago, Myriad Genetics was the undisputed leader of the genetic testing industry. A persistent competitor just challenged the diagnostic company -- and a second one is nipping at its heels.
Here's Why Myriad Genetics Dropped as Much as 10.8% Today
The genetic testing had to revise its full-year fiscal 2019 revenue guidance -- just one quarter into the fiscal year.
Here's Why Myriad Genetics Stock Gained as Much as 14.1% Today
The genetic testing leader announced fiscal fourth-quarter 2018 earnings results and gave guidance for next year. It's the news shareholders have been waiting for.
